argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 nov 2014 - 07:00
Statutaire naam
argenx SE
Titel
arGEN-X - Third Quarter Business Update
Bericht
14 November 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today provides a business update for the third quarter 2014 and financial highlights for the nine months ended 30 September 2014.
RECENT PIPELINE HIGHLIGHTS
• Submitted Investigational New Drug application (IND) to evaluate lead candidate ARGX-110, a novel anti-CD70 therapeutic antibody, in the United States for the treatment of Waldenström's macroglobulinemia (a rare, incurable B-cell lymphoma) in partnership with The Leukemia and Lymphoma Society (LLS)
• Initiated the efficacy evaluation of ARGX-110 in patients with relapsed/refractory CD70-positive T-cell lymphomas as an expansion arm of the ongoing Phase 1b study
• Completed enrolment of first cohort of patients with CD70-positive hematological malignancies into the ongoing Phase 1b expansion trial with ARGX-110
• Completed enrolment of first cohort of patients with CD70-positive solid tumors into the Phase 1b expansion trial with ARGX-110
• Announced positive preclinical data for ARGX-113 supporting its use as a potential breakthrough concept for the treatment of severe autoimmune diseases
• Key patents granted in the US relating to ARGX-110 and ARGX-111, providing patent protection for both until 2031-2032 and allowing for up to an additional five years of patent term extension
• Patent granted reinforcing protection for the SIMPLE Antibody(TM) platform and antibodies in arGEN-X' pipeline
Gerelateerde downloads
Datum laatste update: 27 juli 2024